A Study to Assess the Safety and Tolerability of Anti-MIF Antibody in Subjects With Lupus Nephritis.
Phase of Trial: Phase I
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Imalumab (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions
- Sponsors Baxter Healthcare Corporation
- 21 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Mar 2012 Additional locations (Australia, Canada, Mexico and New Zealand) added as reported by ClinicalTrials.gov.
- 06 Mar 2012 New trial record